Workflow
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
RegeneronRegeneron(US:REGN) ZACKSยท2025-10-09 14:15

Key Takeaways Regeneron gained FDA approval to expand Libtayo as adjuvant therapy for high-risk CSCC.Libtayo cut disease recurrence or death risk by 68% in the late-stage C-POST study.Strong Libtayo sales and new oncology drugs help offset Eylea's competition-driven decline.Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved the label expansion of PD-1 inhibitor Libtayo (cemiplimab-rwlc).Libtayo is now approved as an adjuvant treatment for adult patients with cutaneous squamous cell c ...